SOUTH SAN FRANCISCO - Aligos Therapeutics, Inc. (NASDAQ:ALGS), a company specializing in therapies for liver and viral diseases with a current market capitalization of $96.58 million, announced today ...
Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE ...
Check the time stamp on this data. Updated AI-Generated Signals for Aligos Therapeutics Inc. (ALGS) available here: ALGS.
Below is a month-by-month schedule of all the major esports events that will take place throughout the year 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback